Can antineutrophil cytoplasmic antibody positivity at diagnosis predict the poor outcomes of Sjögren’s syndrome?

Soo Bin Lee, Hyeok Choi, Minyoung Kevin Kim, Seung Min Jung, Jason Jungsik Song, Yong Beom Park, Sang Won Lee

Research output: Contribution to journalArticle

Abstract

We investigated the clinical implication of ANCA positivity at diagnosis on the poor outcomes in patients with Sjögren’s syndrome. The medical records of 606 Korean patients with Sjögren’s syndrome were retrospectively reviewed. The results of perinuclear (P)-ANCA, myeloperoxidase (MPO)-ANCA, cytoplasmic (C)-ANCA, and proteinase 3 (PR3)-ANCA were collected and the frequencies of all-cause mortality, interstitial lung disease (ILD), end-stage renal disease (ESRD), and lymphoma were assessed as the poor outcomes of Sjögren’s syndrome. Comparison of the cumulative patient survivals between the two groups was analysed by the Kaplan–Meier survival analysis. Of the 606 patients, ANCA was detected in 10.2% of Sjögren’s syndrome patients without AAV. Twenty-one patients (3.5%) died, 99 patients (16.3%) suffered from ILD, and 8 patients had ESRD. Lymphoma occurred in 5 patients (0.8%) during 37.5 months. Sjögren’s syndrome patients with ANCA positivity exhibited a lower cumulative ILD-free survival rate than those with ANCA negativity (P = 0.001). Sjögren’s syndrome patients with P-ANCA positivity and those with MPO-ANCA (or P-ANCA) positivity showed a lower cumulative ILD-free survival rate than those without (P = 0.012 and P < 0.001). Also, Sjögren’s syndrome patients with P-ANCA positivity exhibited a lower cumulative ESRD-free survival rate than those without (P = 0.043). ANCA positivity was associated with neither all-cause mortality nor lymphoma in Sjögren’s syndrome patients. ANCA positivity and MPO-ANCA (or P-ANCA) positivity at diagnosis was associated with the development of ILD during follow-up in patients with Sjögren’s syndrome.

Original languageEnglish
JournalRheumatology International
DOIs
Publication statusAccepted/In press - 2019 Jan 1

Fingerprint

Antineutrophil Cytoplasmic Antibodies
Interstitial Lung Diseases
Peroxidase
Disease-Free Survival
Chronic Kidney Failure
Lymphoma
Survival Rate
Myeloblastin
Mortality
Survival Analysis

All Science Journal Classification (ASJC) codes

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Cite this

Lee, Soo Bin ; Choi, Hyeok ; Kim, Minyoung Kevin ; Jung, Seung Min ; Song, Jason Jungsik ; Park, Yong Beom ; Lee, Sang Won. / Can antineutrophil cytoplasmic antibody positivity at diagnosis predict the poor outcomes of Sjögren’s syndrome?. In: Rheumatology International. 2019.
@article{da251e52c8514419b91183b3807e053e,
title = "Can antineutrophil cytoplasmic antibody positivity at diagnosis predict the poor outcomes of Sj{\"o}gren’s syndrome?",
abstract = "We investigated the clinical implication of ANCA positivity at diagnosis on the poor outcomes in patients with Sj{\"o}gren’s syndrome. The medical records of 606 Korean patients with Sj{\"o}gren’s syndrome were retrospectively reviewed. The results of perinuclear (P)-ANCA, myeloperoxidase (MPO)-ANCA, cytoplasmic (C)-ANCA, and proteinase 3 (PR3)-ANCA were collected and the frequencies of all-cause mortality, interstitial lung disease (ILD), end-stage renal disease (ESRD), and lymphoma were assessed as the poor outcomes of Sj{\"o}gren’s syndrome. Comparison of the cumulative patient survivals between the two groups was analysed by the Kaplan–Meier survival analysis. Of the 606 patients, ANCA was detected in 10.2{\%} of Sj{\"o}gren’s syndrome patients without AAV. Twenty-one patients (3.5{\%}) died, 99 patients (16.3{\%}) suffered from ILD, and 8 patients had ESRD. Lymphoma occurred in 5 patients (0.8{\%}) during 37.5 months. Sj{\"o}gren’s syndrome patients with ANCA positivity exhibited a lower cumulative ILD-free survival rate than those with ANCA negativity (P = 0.001). Sj{\"o}gren’s syndrome patients with P-ANCA positivity and those with MPO-ANCA (or P-ANCA) positivity showed a lower cumulative ILD-free survival rate than those without (P = 0.012 and P < 0.001). Also, Sj{\"o}gren’s syndrome patients with P-ANCA positivity exhibited a lower cumulative ESRD-free survival rate than those without (P = 0.043). ANCA positivity was associated with neither all-cause mortality nor lymphoma in Sj{\"o}gren’s syndrome patients. ANCA positivity and MPO-ANCA (or P-ANCA) positivity at diagnosis was associated with the development of ILD during follow-up in patients with Sj{\"o}gren’s syndrome.",
author = "Lee, {Soo Bin} and Hyeok Choi and Kim, {Minyoung Kevin} and Jung, {Seung Min} and Song, {Jason Jungsik} and Park, {Yong Beom} and Lee, {Sang Won}",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s00296-019-04476-5",
language = "English",
journal = "Rheumatology International",
issn = "0172-8172",
publisher = "Springer Verlag",

}

Can antineutrophil cytoplasmic antibody positivity at diagnosis predict the poor outcomes of Sjögren’s syndrome? / Lee, Soo Bin; Choi, Hyeok; Kim, Minyoung Kevin; Jung, Seung Min; Song, Jason Jungsik; Park, Yong Beom; Lee, Sang Won.

In: Rheumatology International, 01.01.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Can antineutrophil cytoplasmic antibody positivity at diagnosis predict the poor outcomes of Sjögren’s syndrome?

AU - Lee, Soo Bin

AU - Choi, Hyeok

AU - Kim, Minyoung Kevin

AU - Jung, Seung Min

AU - Song, Jason Jungsik

AU - Park, Yong Beom

AU - Lee, Sang Won

PY - 2019/1/1

Y1 - 2019/1/1

N2 - We investigated the clinical implication of ANCA positivity at diagnosis on the poor outcomes in patients with Sjögren’s syndrome. The medical records of 606 Korean patients with Sjögren’s syndrome were retrospectively reviewed. The results of perinuclear (P)-ANCA, myeloperoxidase (MPO)-ANCA, cytoplasmic (C)-ANCA, and proteinase 3 (PR3)-ANCA were collected and the frequencies of all-cause mortality, interstitial lung disease (ILD), end-stage renal disease (ESRD), and lymphoma were assessed as the poor outcomes of Sjögren’s syndrome. Comparison of the cumulative patient survivals between the two groups was analysed by the Kaplan–Meier survival analysis. Of the 606 patients, ANCA was detected in 10.2% of Sjögren’s syndrome patients without AAV. Twenty-one patients (3.5%) died, 99 patients (16.3%) suffered from ILD, and 8 patients had ESRD. Lymphoma occurred in 5 patients (0.8%) during 37.5 months. Sjögren’s syndrome patients with ANCA positivity exhibited a lower cumulative ILD-free survival rate than those with ANCA negativity (P = 0.001). Sjögren’s syndrome patients with P-ANCA positivity and those with MPO-ANCA (or P-ANCA) positivity showed a lower cumulative ILD-free survival rate than those without (P = 0.012 and P < 0.001). Also, Sjögren’s syndrome patients with P-ANCA positivity exhibited a lower cumulative ESRD-free survival rate than those without (P = 0.043). ANCA positivity was associated with neither all-cause mortality nor lymphoma in Sjögren’s syndrome patients. ANCA positivity and MPO-ANCA (or P-ANCA) positivity at diagnosis was associated with the development of ILD during follow-up in patients with Sjögren’s syndrome.

AB - We investigated the clinical implication of ANCA positivity at diagnosis on the poor outcomes in patients with Sjögren’s syndrome. The medical records of 606 Korean patients with Sjögren’s syndrome were retrospectively reviewed. The results of perinuclear (P)-ANCA, myeloperoxidase (MPO)-ANCA, cytoplasmic (C)-ANCA, and proteinase 3 (PR3)-ANCA were collected and the frequencies of all-cause mortality, interstitial lung disease (ILD), end-stage renal disease (ESRD), and lymphoma were assessed as the poor outcomes of Sjögren’s syndrome. Comparison of the cumulative patient survivals between the two groups was analysed by the Kaplan–Meier survival analysis. Of the 606 patients, ANCA was detected in 10.2% of Sjögren’s syndrome patients without AAV. Twenty-one patients (3.5%) died, 99 patients (16.3%) suffered from ILD, and 8 patients had ESRD. Lymphoma occurred in 5 patients (0.8%) during 37.5 months. Sjögren’s syndrome patients with ANCA positivity exhibited a lower cumulative ILD-free survival rate than those with ANCA negativity (P = 0.001). Sjögren’s syndrome patients with P-ANCA positivity and those with MPO-ANCA (or P-ANCA) positivity showed a lower cumulative ILD-free survival rate than those without (P = 0.012 and P < 0.001). Also, Sjögren’s syndrome patients with P-ANCA positivity exhibited a lower cumulative ESRD-free survival rate than those without (P = 0.043). ANCA positivity was associated with neither all-cause mortality nor lymphoma in Sjögren’s syndrome patients. ANCA positivity and MPO-ANCA (or P-ANCA) positivity at diagnosis was associated with the development of ILD during follow-up in patients with Sjögren’s syndrome.

UR - http://www.scopus.com/inward/record.url?scp=85075217312&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075217312&partnerID=8YFLogxK

U2 - 10.1007/s00296-019-04476-5

DO - 10.1007/s00296-019-04476-5

M3 - Article

C2 - 31720749

AN - SCOPUS:85075217312

JO - Rheumatology International

JF - Rheumatology International

SN - 0172-8172

ER -